Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13946703 | 0.83 | HRH3 (0.54) | KMT2AL3MBTL1RAB9ASMN1; SMN2HRH3 | |
| SCHEMBL15242991 | 0.83 | L3MBTL1 (0.45) | KMT2AL3MBTL1RAB9ASMN1; SMN2HRH3 | |
| SCHEMBL4893979 | 0.83 | KMT2A (0.49) | KMT2AL3MBTL1RAB9ASMN1; SMN2HRH3 | |
| SCHEMBL2132367 | 0.83 | L3MBTL1 (0.60) | KMT2AMAPTL3MBTL1RAB9ASMN1; SMN2 | |
| SCHEMBL6824717 | 0.83 | L3MBTL1 (0.65) | KMT2APOLBTDP1L3MBTL1HRH3 | |
| SCHEMBL917005 | 0.81 | L3MBTL1 (0.68) | KMT2AMAPTL3MBTL1RAB9ASMN1; SMN2 | |
| SCHEMBL14199640 | 0.81 | ALDH1A1 (0.51) | KMT2APOLBL3MBTL1SMN1; SMN2HRH3 | |
| SCHEMBL2535861 | 0.80 | PARP1 (0.41) | KMT2APOLBTDP1L3MBTL1RAB9A | |
| SCHEMBL4093054 | 0.80 | MCHR1 (0.51) | MAPTL3MBTL1RAB9ASMN1; SMN2HRH3 | |
| SCHEMBL5872163 | 0.80 | L3MBTL1 (0.71) | MAPTL3MBTL1RAB9ASMN1; SMN2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642256-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2010-01-05 | — | — | US | disclosed |
| US-7642256-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2010-01-05 | — | — | US | disclosed |
| US-7642256-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2010-01-05 | — | — | US | disclosed |
| US-7566735-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| US-7566735-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| US-7566735-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| CN-101448792-A | Compounds that potentiate AMPA receptors and their use in medicine | GLAXO GROUP LTD (GB) | 2009-06-03 | — | — | CN | disclosed |
| US-20090118280-A1 | Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine | HARRISON STEPHEN | 2009-05-07 | — | — | US | disclosed |
| US-20090118280-A1 | Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine | HARRISON STEPHEN | 2009-05-07 | — | — | US | disclosed |
| US-20090118280-A1 | Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine | HARRISON STEPHEN | 2009-05-07 | — | — | US | disclosed |
| EP-1996555-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-12-03 | — | — | EP | disclosed |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| WO-2007107539-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107539-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118280-A1 | Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine | GRIN1, GRM2, GRM1 | KMT2A 2334/4885POLB 3092/4885TDP1 3075/4885 |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GRIN1, GRM2, GRM1 | KMT2A 2334/4885POLB 3092/4885TDP1 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.